Developing biomarkers to detect and predict outcomes of early-stage lung cancer
Microbial and host biomarker development for detection and prognosis of early stage non-small cell lung cancer
This study is looking for helpful signs in blood and lung samples that can spot non-small cell lung cancer early and tell if a lung nodule is cancerous or not, which could lead to better treatment for patients with early-stage lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11081756 on NIH RePORTER |
What this research studies
This research focuses on identifying microbial and host biomarkers that can help in the early detection and prognosis of non-small cell lung cancer (NSCLC). By analyzing blood samples and lower airway signatures, the study aims to develop non-invasive diagnostic tools that can accurately differentiate between malignant and non-malignant lung nodules. The approach utilizes advanced techniques to characterize the microbiome and identify RNA signatures associated with lung cancer, potentially leading to better patient outcomes. Patients with early-stage NSCLC may benefit from these findings, which could improve diagnostic accuracy and treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage non-small cell lung cancer or those with indeterminate lung nodules.
Not a fit: Patients with advanced-stage lung cancer or those without lung nodules may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and less invasive methods for diagnosing lung cancer and predicting patient outcomes.
How similar studies have performed: Other research has shown promise in using microbial signatures for cancer diagnosis, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Segal, Leopoldo Nicolas — New York University School of Medicine
- Study coordinator: Segal, Leopoldo Nicolas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.